FDA Approves Akebia Therapeutics' Vafseo to Treat Anemia in Chronic Kidney Disease Patients

Thursday, 28 March 2024, 15:50

The FDA has given the green light to Akebia Therapeutics' Vafseo tablets to address anemia associated with chronic kidney disease in adults undergoing dialysis for over three months. Vafseo, an innovative HIF-PH inhibitor, promotes endogenous erythropoietin production to manage anemia effectively. With approval in over 37 countries, Vafseo represents a significant advancement in anemia treatment for CKD patients.

https://store.livarava.com/abfe8a1f-ed5b-11ee-8907-87cc5c87fb08.png — FDA Approves Akebia Therapeutics' Vafseo to Treat Anemia in Chronic Kidney Disease Patients

FDA Approval for Akebia Therapeutics

On Wednesday, the FDA officially approved Akebia Therapeutics Inc's Vafseo tablets for treating anemia related to chronic kidney disease in adult dialysis patients.

Innovative Anemia Management

Vafseo is a once-daily oral HIF-PH inhibitor that triggers the body's response to hypoxia, stimulating natural production of erythropoietin to regulate anemia.

Global Approval

Vafseo's approval extends to 37 countries, marking a significant milestone in providing an effective treatment for anemia in CKD patients.

This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.